Test Price
850 AED✅ Home Collection Available
PML/RARA Quantitative [Single Form] Test in UAE
Executive Summary & Core Metrics
✅ 99.9% Diagnostic Sensitivity – ISO 15189 Accredited qPCR
🚚 VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Peripheral Blood) – Available daily from 8 AM to 11 PM
🩺 Post-Test Clinical Guidance – Telephonic Interpretation by Consultant Medical Geneticist
📱 Insurance Direct Billing Verification – WhatsApp +971 54 548 8731
Test Overview & Methodology
The PML/RARA Quantitative (Single Form) assay precisely measures the t(15;17) fusion transcript by Real-Time PCR (qPCR), the hallmark of acute promyelocytic leukemia (APL). This DHA-regulated genetic test distinguishes the specific bcr1, bcr2, or bcr3 transcript variant and monitors minimal residual disease (MRD) with unmatched sensitivity.
| Feature | Our Test (PML/RARA qPCR) | Conventional FISH / Karyotyping |
|---|---|---|
| Precision | Quantitative detection of 1 leukemic cell in 10,000 | Qualitative / semi-quantitative; resolution ~1 in 100–200 |
| Methodology | Real-Time PCR (qPCR) + optional Whole Genome Sequencing (WGS) confirmation | Fluorescence In Situ Hybridization or G-banding |
| Turnaround Time | 2–3 Days | 5–14 Days |
| MRD Monitoring | Gold standard for treatment response and early relapse prediction | Limited; not recommended for MRD |
| Regulatory Compliance | Full alignment with ISO 15189 and DHA molecular diagnostics guidelines | Variable; often lacks quantitative MRD validation |
Physician Insight & Safety Protocols
"PML/RARA quantification is the molecular cornerstone of APL treatment monitoring. This assay must always be interpreted alongside bone marrow morphology, complete blood counts, and coagulation profiles. A negative qPCR result does not exclude extramedullary relapse or emerging resistance mutations — clinical judgment remains paramount in therapeutic decision-making."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Medication Advisory
⚠️ Ongoing Therapy Continuation Required
Do not discontinue all-trans retinoic acid (ATRA), arsenic trioxide, or any prescribed chemotherapy regimen without direct consultation with your treating oncologist. Abrupt cessation of these agents can trigger life-threatening differentiation syndrome, hyperleukocytosis, or coagulopathic decompensation. This laboratory result is intended to guide therapy adjustments — not to replace clinical oversight.
Patient Exclusion Criteria & Emergency Red Flags
- Absolute Contraindications: Active severe coagulopathy (INR greater than 2.0, platelets below 20×10⁹/L) without prior medical clearance; clinical signs of acute intracranial hemorrhage or uncontrolled bleeding diathesis.
- Relative Exclusion for Home Collection: Inability to obtain peripheral venous access due to poor vasculature; unaccompanied minors under 18 years of age per DHA pediatric care guidelines.
- Mandatory Emergency Department Evaluation: Sudden severe headache, visual field changes, spontaneous bruising or bleeding, unexplained dyspnea, or altered level of consciousness — these may indicate leukostasis, central nervous system involvement, or bleeding crisis requiring immediate hospital-based care.
- Pre-Procedure Requirements: A valid treating physician referral is required for sample collection and interpretation. Patients with unexplained fever, active coagulopathy, or suspected APL should undergo bone marrow aspiration in a hospital setting rather than peripheral blood draw.
Patient FAQ & Clinical Guidance
1. What does a positive PML/RARA quantitative result mean?
A detectable PML-RARA fusion transcript indicates the presence of leukemic cells carrying the t(15;17) translocation. This finding requires immediate correlation with bone marrow morphology and peripheral blood counts to guide treatment adjustment. The quantitative value helps track disease burden and response to therapy over time.
2. How should I prepare for the PML/RARA test?
No special dietary or medication preparation is required for a peripheral blood draw. Patients scheduled for bone marrow aspiration as part of their evaluation must follow fasting instructions and medication adjustment guidelines provided by their hematologist. Continue all prescribed medications unless explicitly directed otherwise by your physician.
3. How accurate is qPCR compared to older testing methods?
Quantitative real-time PCR achieves greater than 99.9% sensitivity, detecting one leukemic cell among 10,000 normal cells. This makes it the gold standard for minimal residual disease monitoring, significantly outperforming conventional FISH or cytogenetic analysis which typically detect only one abnormal cell in 100 to 200 cells.
4. How long does it take to receive my PML/RARA test results?
Results are typically available within 2 to 3 business days from sample collection. Our laboratory processes all specimens under ISO 15189 accredited protocols to ensure both accuracy and timeliness. Urgent clinical requests can be expedited upon physician coordination.
5. Can this test be performed during pregnancy or while breastfeeding?
Yes, the peripheral blood draw for PML/RARA qPCR poses minimal risk during pregnancy or breastfeeding. However, the test should only be ordered when clinically indicated by a treating physician who is managing the patient's leukemia treatment. Always inform your phlebotomist and physician about your pregnancy or lactation status before sample collection.
UAE Regulatory & Data Privacy Adherence
Data Protection & Confidentiality: All patient genetic data generated from this test is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Additionally, the use of information and communication technology in health fields strictly follows Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and informed consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | PML/RARA Quantitative [Single Form] |
| Price (AED) | 850 |
| Turnaround Time | 2–3 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA); Bone Marrow Aspirate if clinically indicated |
| Methodology Used | Real-Time Quantitative PCR (qPCR) – ISO 15189 Accredited |
| ICD-10-CM Code | C92.4 |
| LOINC Code | 76490-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians